Marshall Wace
COGT icon

Marshall Wace’s Cogent Biosciences COGT Stock Holding History

Marshall Wace’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.3M Sell
706,153
-894,015
-56% -$31.3M 0.02% 589
2026
Q1 		$61.6M Sell
1,600,168
-60,567
-4% -$2.24M 0.06% 294
2025
Q4 		$59M Buy
1,660,735
+1,018,256
+158% +$28.6M 0.05% 307
2025
Q3 		$9.23M Buy
+642,479
New +$7.61M 0.01% 942
2024
Q4 		– Sell
-73,905
Closed -$798K – 2628
2024
Q3 		$798K Buy
+73,905
New +$720K ﹤0.01% 1741
2024
Q1 		– Sell
-49,466
Closed -$291K – 2487
2023
Q4 		$291K Sell
49,466
-2,137,832
-98% -$16.4M ﹤0.01% 1898
2023
Q3 		$21.3M Buy
2,187,298
+33,211
+2% +$394K 0.04% 415
2023
Q2 		$25.5M Buy
2,154,087
+344,708
+19% +$3.95M 0.05% 395
2023
Q1 		$19.5M Buy
1,809,379
+328,721
+22% +$4.2M 0.04% 476
2022
Q4 		$17.1M Buy
+1,480,658
New +$18.3M 0.04% 519
2022
Q3 		– Sell
-1,625,817
Closed -$14.7M – 3396
2022
Q2 		$14.7M Buy
1,625,817
+833,833
+105% +$5.69M 0.03% 632
2022
Q1 		$5.93M Sell
791,984
-210,266
-21% -$1.46M 0.01% 1237
2021
Q4 		$8.6M Buy
+1,002,250
New +$8.71M 0.02% 969
2019
Q1 		– Sell
-7,869
Closed -$138K – 1759
2018
Q4 		$138K Buy
+7,869
New +$233K ﹤0.01% 1324

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Marshall Wace's COGT Position: Q2 2026 in Review

Marshall Wace reduced its Cogent Biosciences (COGT) stake by 56% in Q2 2026, selling an estimated $31.3M and leaving 706,153 shares worth $27.3M. The position accounts for 0.02% of the portfolio, ranked #589.

Marshall Wace first reported a position in COGT in Q4 2018 and has held it in 14 quarters since. The position peaked at $61.6M in Q1 2026. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Marshall Wace held 706,153 shares of Cogent Biosciences worth $27.3M as of Q2 2026.
  • Marshall Wace sold 894,015 Cogent Biosciences shares in Q2 2026, an estimated $31.3M.
  • Cogent Biosciences made up 0.02% of Marshall Wace's portfolio in Q2 2026, its #589 holding.
  • Marshall Wace first reported a position in Cogent Biosciences in Q4 2018 and has held it in 14 quarters since.
  • Marshall Wace's Cogent Biosciences position peaked at $61.6M in Q1 2026.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.